COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Déclaration de transactions sur actions propres
13/04/2026
Déclaration de transactions sur actions propres Paris, France (13 avril 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 7 avril 2026, les [...]
Sienna for Seniors Foundation $1 Million Gift Advances Healthy Aging Research at Ontario Tech University
13/04/2026
Contribution will support work exploring older adult well-being, happiness, engagement and connection Pictured (left to right): John Henry, Regional Chair, Durham Region; Nitin Jain, President and CEO, Sienna Senior [...]
IBA – ACQUISITION OF OWN SHARES
13/04/2026
Louvain-la-Neuve, Belgium, April 13 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Rica’s Coyol Free Trade Zone
13/04/2026
BROOKLYN PARK, MN, April 13, 2026 (GLOBE NEWSWIRE) -- Switchback Medical, a medical device contract development and manufacturing organization (CDMO), announced it has signed a lease for a new 18,000-square-foot [...]
EmPRO Reports Another Year of Strong Financial Results with Significant Growth in Net Income and Surplus During 2025
13/04/2026
ROSLYN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- EmPRO Insurance Company (EmPRO), a licensed medical professional liability insurance carrier serving physicians and healthcare facilities, today announced strong [...]
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
13/04/2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- [...]
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
13/04/2026
Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in patients with advanced [...]
SafeSpace Global Corporation Announces Operational Expansion to Support Commercial Deployment of its AI-safety platform and Growing Revenue Activities
13/04/2026
KNOXVILLE, TN., April 13, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation ("SafeSpace" or the "Company") (OTCID: SSGC), a leader in multimodal AI-powered safety and security solutions, dedicated to safety [...]
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
13/04/2026
Acquisition expands BiomX’s defense portfolio with aligned capabilities designed to integrate across detection, analysis, and response, reinforcing its position in AI-enabled security systems NETANYA, Israel, April 13, [...]
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
13/04/2026
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
13/04/2026
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026
AKB-9090 is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a [...]
Catheter Precision Announces Accepted Publication in Leading European Medical Journal
13/04/2026
Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular Procedures FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company [...]
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
13/04/2026
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE [...]
ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update
13/04/2026
– Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – – LA-PDAC program represents large market opportunity [...]
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
13/04/2026
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total [...]
CVRx Reports Preliminary First Quarter 2026 Financial Results
13/04/2026
Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 Early data in 2026 shows an increase in the 30- [...]
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
13/04/2026
Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis to present 3 oral [...]
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
13/04/2026
Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug [...]

Pages